Zealand Pharma
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
Company announcement – No. 8 / 2025
Total number of shares and voting rights in Zealand Pharma as of March 31, 2025
Copenhagen, Denmark, March 31, 2025 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its share capital have occurred.
In Company Announcement No. 5 / 2025 dated March 20, 2025, Zealand Pharma announced a share capital increase due to the exercise of employee warrants. Following this announcement, the table below details the total number of shares and voting rights in Zealand Pharma as of March 31, 2025.
| Date | Number of shares (nominal value of DKK 1 each) | Share capital (nominal value in DKK) | Number of voting rights |
| March 31, 2025 | 71,051,296 | 71,051,296 | 71,051,296 |
The Company's Articles of Association are available on the Company's website https://www.zealandpharma.com.
# # #
About Zealand Pharma A/S
Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of blue-chip pharma companies as well as commercial partnerships for its marketed products.
Zealand was founded in 1998 and is headquartered in Copenhagen, Denmark, with a presence in the United States. For more information about Zealand’s business and activities, please visit www.zealandpharma.com.
Contact
Adam Lange
Investor Relations Officer
Zealand Pharma
Email: alange@zealandpharma.com
Anna Krassowska, PhD
Vice President, Investor Relations & Corporate Communications
Zealand Pharma
Email: akrassowska@zealandpharma.com
Neshat Ahmadi
Investor Relations Manager
Zealand Pharma
Email: neahmadi@zealandpharma.com
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Nykredit Realkredit A/S2.4.2025 11:31:13 CEST | Pressemeddelelse
Nykredit Realkredit A/S: Ledende medarbejdere og disses nærtstående transaktioner
Nykredit Realkredit A/S2.4.2025 11:26:56 CEST | Pressemeddelelse
Nykredit Realkredit A/S: Ledende medarbejdere og disses nærtstående transaktioner
Nykredit Realkredit A/S2.4.2025 11:21:50 CEST | Pressemeddelelse
Nykredit Realkredit A/S: Ledende medarbejdere og disses nærtstående transaktioner
Helsinn Healthcare S.A.2.4.2025 11:00:00 CEST | Press release
Helsinn Group submits a new formulation of AKYNZEO® to the European Medicines Agency (EMA)
CoinShares International Limited2.4.2025 11:00:00 CEST | Press release
CoinShares Resolves on Dividend Distribution for the financial year 2024
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom